OBJECTIVE: To report a technique for partial prostatectomy by laser dissection and to evaluate outcome and complications in dogs with prostate carcinoma (PCA). STUDY DESIGN: Experimental and clinical case series. ANIMALS: Four normal dogs and 8 dogs with PCA. METHODS: Subcapsular partial prostatectomy, sparing the urethra and the dorsal aspect of the prostatic capsule, using Nd:YAG laser dissection to remove the prostatic parenchyma and control hemorrhage was performed in 4 normal dogs and subsequently in 8 dogs with histologically confirmed PCA. Additional treatment of PCA dogs included local application of interleukin-2 and systemic administration of meloxicam. Prostate size, complications, and survival time were recorded. Laser-associated thermal damage to surrounding tissue was evaluated by histology. RESULTS: In normal dogs, no damage to the dorsal prostatic capsule or urethra was detected. In PCA dogs, median survival was 103 days (range, 5-239 days). Three dogs died from complications within 16 days, whereas 5 (median survival, 183 days; range, 91-239 days) had improvement or resolution of clinical signs. Urinary incontinence did not occur. CONCLUSION: Laser assisted subcapsular partial prostatectomy can be performed in dogs with PCA without development of postoperative incontinence. CLINICAL RELEVANCE: Subcapsular partial prostatectomy is a potential palliative treatment for PCA in dogs and may lead to the resolution of clinical signs for several months.
OBJECTIVE: To report a technique for partial prostatectomy by laser dissection and to evaluate outcome and complications in dogs with prostate carcinoma (PCA). STUDY DESIGN: Experimental and clinical case series. ANIMALS: Four normal dogs and 8 dogs with PCA. METHODS: Subcapsular partial prostatectomy, sparing the urethra and the dorsal aspect of the prostatic capsule, using Nd:YAG laser dissection to remove the prostatic parenchyma and control hemorrhage was performed in 4 normal dogs and subsequently in 8 dogs with histologically confirmed PCA. Additional treatment of PCA dogs included local application of interleukin-2 and systemic administration of meloxicam. Prostate size, complications, and survival time were recorded. Laser-associated thermal damage to surrounding tissue was evaluated by histology. RESULTS: In normal dogs, no damage to the dorsal prostatic capsule or urethra was detected. In PCA dogs, median survival was 103 days (range, 5-239 days). Three dogs died from complications within 16 days, whereas 5 (median survival, 183 days; range, 91-239 days) had improvement or resolution of clinical signs. Urinary incontinence did not occur. CONCLUSION: Laser assisted subcapsular partial prostatectomy can be performed in dogs with PCA without development of postoperative incontinence. CLINICAL RELEVANCE: Subcapsular partial prostatectomy is a potential palliative treatment for PCA in dogs and may lead to the resolution of clinical signs for several months.
Authors: Eduardo de Paula Nascente; Renée Laufer Amorim; Carlos Eduardo Fonseca-Alves; Veridiana Maria Brianezi Dignani de Moura Journal: Cancers (Basel) Date: 2022-05-31 Impact factor: 6.575
Authors: Toby Ryman-Tubb; Jennifer H Lothion-Roy; Veronika M Metzler; Anna E Harris; Brian D Robinson; Albert A Rizvanov; Jennie N Jeyapalan; Victoria H James; Gary England; Catrin S Rutland; Jenny L Persson; Lukas Kenner; Mark A Rubin; Nigel P Mongan; Simone de Brot Journal: Vet Med Sci Date: 2021-10-10